Intra-articular Injection in the Knee of Adipose Derived Stromal Cells and Platelet Rich Plasma for Osteoarthritis
Launched by BIOHEART, INC. · Mar 20, 2017
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients age 50 or older who present with symptomatic primary osteoarthritis of the knee
- • daily pain for the previous 3 months
- • analgesics usage at least once a week
- • less than 30 minutes of morning stiffness
- • WOMAC score of ≤ 75 in the target knee
- • Brandt Radiographic Grading Scale of Osteoarthritis grade 1 and 2
- Exclusion Criteria:
- • evidence of secondary knee osteoarthritis
- • severe osteoarthritis (Joint space width - JSW \< 2 mm)
- • prior intra articular injections within the previous one year prior to inclusion
- • patients with clinically significant systemic disease
About Bioheart, Inc.
BioHeart, Inc. is a pioneering biotechnology company dedicated to advancing regenerative medicine through innovative therapies for heart diseases. Focused on harnessing the potential of stem cells and tissue engineering, BioHeart aims to develop effective solutions that not only treat but also repair damaged cardiac tissue. With a commitment to clinical excellence and patient-centered research, BioHeart collaborates with leading medical professionals and institutions to conduct rigorous clinical trials, ensuring the safety and efficacy of its groundbreaking treatments. The company's vision is to transform the landscape of cardiovascular care, improving the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials